IKT: Inhibikase Therapeutics, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Activist and 5% holders
| Filed | What | Holder | Stake | Change | Filing |
|---|---|---|---|---|---|
| 2026-08-14 | 13G amendment | Perceptive Advisors LLC | 6.90% | SEC | |
| 2026-08-14 | Fell below 5% | Nantahala Capital Management, LLC | 4.30% | SEC | |
| 2026-08-13 | 13G amendment | Sands Capital Life Sciences Pulse Fund II, L.P. | 9.30% | SEC | |
| 2026-07-31 | 13G amendment | RA Capital Management, L.P. | 9.90% | SEC | |
| 2026-07-28 | New 13G stake | BlackRock, Inc. | 5.90% | SEC |
Institutional ownership (Q2 2026)
105 institutions reported holding $252.24M of Inhibikase Therapeutics, Inc. on Form 13F (104 the quarter before). 18 opened a new position and 14 sold out. Shares held by institutions: +6%.
| Largest holders | Shares | Value |
|---|---|---|
| Sands Capital Alternatives, LLC | 13,018,965 | $26.43M |
| Soleus Capital Management, L.P. | 10,875,000 | $22.08M |
| Trails Edge Capital Partners, LP | 9,051,318 | $18.37M |
| Fairmount Funds Management LLC | 8,625,000 | $17.51M |
| BlackRock, Inc. | 7,768,057 | $15.77M |
| Kalehua Capital Management LLC | 7,643,780 | $15.52M |
| ADAR1 Capital Management, LLC | 7,387,205 | $15.00M |
| Blackstone Inc. | 5,938,276 | $12.05M |
| Siren, L.L.C. | 5,850,000 | $11.88M |
| Nantahala Capital Management, LLC | 5,403,726 | $10.97M |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.